Compare PAYO & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | KOD |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2021 | 2018 |
| Metric | PAYO | KOD |
|---|---|---|
| Price | $7.12 | $37.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $7.69 | ★ $35.43 |
| AVG Volume (30 Days) | ★ 3.5M | 554.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $1,052,774,000.00 | N/A |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $10.28 | N/A |
| P/E Ratio | $142.00 | ★ N/A |
| Revenue Growth | ★ 7.68 | N/A |
| 52 Week Low | $4.08 | $8.30 |
| 52 Week High | $7.18 | $47.84 |
| Indicator | PAYO | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 41.64 |
| Support Level | $7.08 | $32.93 |
| Resistance Level | $7.16 | $46.29 |
| Average True Range (ATR) | 0.03 | 2.44 |
| MACD | -0.01 | -0.40 |
| Stochastic Oscillator | 64.29 | 26.66 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.